MENU
+Compare
IMUX
Stock ticker: NASDAQ
AS OF
Oct 14, 04:59 PM (EDT)
Price
$0.84
Change
-$0.05 (-5.62%)
Capitalization
82.89M

IMUX Immunic Forecast, Technical & Fundamental Analysis

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMUX with price predictions
Oct 08, 2025

IMUX's Stochastic Oscillator descends into oversold zone

The Stochastic Oscillator for IMUX moved into oversold territory on October 08, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 08, 2025. You may want to consider a long position or call options on IMUX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on September 18, 2025. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

IMUX moved above its 50-day moving average on October 08, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IMUX crossed bullishly above the 50-day moving average on October 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 143 cases where IMUX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMUX broke above its upper Bollinger Band on September 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.444) is normal, around the industry mean (23.456). P/E Ratio (0.000) is within average values for comparable stocks, (54.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.164). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (347.799).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMUX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMUX is expected to report earnings to fall 21.65% to -15 cents per share on November 06

Immunic IMUX Stock Earnings Reports
Q3'25
Est.
$-0.16
Q2'25
Missed
by $0.03
Q1'25
Missed
by $0.03
Q4'24
Missed
by $0.01
Q3'24
Missed
by $0.02
The last earnings report on August 07 showed earnings per share of -20 cents, missing the estimate of -17 cents. With 1.63M shares outstanding, the current market capitalization sits at 82.89M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CPPCY13.17N/A
N/A
CP All Public Co Ltd
SJMHY1.59N/A
N/A
SJM Holdings Ltd.
SMREF0.14N/A
N/A
Sun Summit Minerals Corp
ELLRY2.68N/A
N/A
Elringklinger Ag
USLIF0.01N/A
N/A
AMERICAN SALARS LITHIUM INC

IMUX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with ORIC. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then ORIC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
-0.43%
ORIC - IMUX
34%
Loosely correlated
+1.68%
NTLA - IMUX
32%
Poorly correlated
-3.10%
PLRX - IMUX
31%
Poorly correlated
+1.36%
REVB - IMUX
31%
Poorly correlated
-5.63%
KOD - IMUX
30%
Poorly correlated
-2.27%
More